SG11201400205QA - Selective and reversible inhibitors of ubiquitin specific protease 7 - Google Patents
Selective and reversible inhibitors of ubiquitin specific protease 7Info
- Publication number
- SG11201400205QA SG11201400205QA SG11201400205QA SG11201400205QA SG11201400205QA SG 11201400205Q A SG11201400205Q A SG 11201400205QA SG 11201400205Q A SG11201400205Q A SG 11201400205QA SG 11201400205Q A SG11201400205Q A SG 11201400205QA SG 11201400205Q A SG11201400205Q A SG 11201400205QA
- Authority
- SG
- Singapore
- Prior art keywords
- selective
- specific protease
- reversible inhibitors
- ubiquitin specific
- ubiquitin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11306096A EP2565186A1 (en) | 2011-09-02 | 2011-09-02 | Selective and reversible inhibitors of ubiquitin specific protease 7 |
PCT/EP2012/066741 WO2013030218A1 (en) | 2011-09-02 | 2012-08-29 | Selective and reversible inhibitors of ubiquitin specific protease 7 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201400205QA true SG11201400205QA (en) | 2014-03-28 |
Family
ID=46750347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201400205QA SG11201400205QA (en) | 2011-09-02 | 2012-08-29 | Selective and reversible inhibitors of ubiquitin specific protease 7 |
Country Status (24)
Country | Link |
---|---|
US (1) | US9546150B2 (es) |
EP (2) | EP2565186A1 (es) |
JP (1) | JP6059228B2 (es) |
KR (1) | KR20140085430A (es) |
CN (1) | CN103930415B (es) |
AR (1) | AR087757A1 (es) |
AU (1) | AU2012300944B2 (es) |
BR (1) | BR112014004649A2 (es) |
CA (1) | CA2847017A1 (es) |
CL (1) | CL2014000511A1 (es) |
DK (1) | DK2751092T3 (es) |
ES (1) | ES2594603T3 (es) |
HU (1) | HUE029418T2 (es) |
IL (1) | IL231203A (es) |
LT (1) | LT2751092T (es) |
MA (1) | MA35361B1 (es) |
MX (1) | MX340500B (es) |
PL (1) | PL2751092T3 (es) |
PT (1) | PT2751092T (es) |
RU (1) | RU2622640C2 (es) |
SG (1) | SG11201400205QA (es) |
SI (1) | SI2751092T1 (es) |
TN (1) | TN2014000079A1 (es) |
WO (1) | WO2013030218A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
AU2013370417A1 (en) | 2012-12-28 | 2015-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof |
CN105327350A (zh) * | 2014-07-23 | 2016-02-17 | 中国科学院上海巴斯德研究所 | 泛素化途径相关因子在调控辅助性t细胞功能中的应用 |
MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
TWI698436B (zh) * | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
EP3253765A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
WO2016126926A1 (en) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
JP2018504432A (ja) * | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス,インコーポレイテッド | ユビキチン特異的プロテアーゼ7阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン |
CN105251020B (zh) * | 2015-09-29 | 2018-10-09 | 武汉大学 | 泛素特异性蛋白酶4(usp4)在治疗心肌肥厚中的功能及应用 |
GB201522267D0 (en) * | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
GB201602854D0 (en) * | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
EP3468971B1 (en) * | 2016-06-10 | 2020-02-19 | Les Laboratoires Servier | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them |
FR3052451B1 (fr) * | 2016-06-10 | 2018-06-22 | Les Laboratoires Servier | Nouveaux derives de piperidinyle hetero(aryl)-substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3061177B1 (fr) * | 2016-12-28 | 2019-09-27 | Les Laboratoires Servier | Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
FR3052452B1 (fr) | 2016-06-10 | 2018-06-22 | Les Laboratoires Servier | Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2018009812A1 (en) | 2016-07-08 | 2018-01-11 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
GB201612938D0 (en) * | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
WO2018081897A1 (en) * | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
US11059809B2 (en) | 2017-06-20 | 2021-07-13 | Mission Therapeutics Limited | Substituted cyanopyrrolidines with activity as DUB inhibitors |
WO2019067503A1 (en) * | 2017-09-26 | 2019-04-04 | Dana-Farber Cancer Institute, Inc. | NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
EP3870179A4 (en) * | 2018-10-22 | 2022-11-23 | Dana Farber Cancer Institute, Inc. | INHIBITION OF USP7 |
BR112021010644A2 (pt) * | 2018-12-06 | 2021-09-28 | Almac Discovery Limited | Composto, estereoisômero, tautômero, hidrato, derivado de n-óxido ou sal farmaceuticamente aceitável, composição farmacêutica, métodos para tratamento de obesidade, resistência a insulina, diabetes tipo ii, atrofia muscular e câncer e para redução de perda de massa muscular em um indivíduo, e, inibidor de usp19 |
US20220125760A1 (en) | 2019-02-14 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of usp7 inhibitors for the treatment of acute myeloid leukemia (aml) |
GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
KR20220042379A (ko) * | 2019-07-15 | 2022-04-05 | 온코아렌디 테라퓨틱스 에스.에이. | 키티나제 억제제로서 유용한 치환된 아미노 트리아졸 |
GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
CN113087718B (zh) * | 2020-01-09 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | 噻吩并嘧啶酮类化合物及其医药应用 |
GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
CN115427076A (zh) * | 2020-02-28 | 2022-12-02 | 免疫学有限公司 | 用于治疗冠状病毒感染的人去泛素化酶抑制剂 |
JP2023520727A (ja) | 2020-04-08 | 2023-05-18 | ミッション セラピューティクス リミティド | Usp30阻害剤として活性を有するn-シアノピロリジン |
WO2021242760A1 (en) * | 2020-05-26 | 2021-12-02 | Lowell Therapeutics, Inc. | Methods of treating viral infection using protease inhibitors |
BR112022020644A2 (pt) | 2020-05-28 | 2022-12-06 | Mission Therapeutics Ltd | Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial |
JP2023529570A (ja) | 2020-06-04 | 2023-07-11 | ミッション セラピューティクス リミティド | Usp30阻害剤としての活性を有するn-シアノピロリジン |
AU2021286831A1 (en) | 2020-06-08 | 2023-02-02 | Mission Therapeutics Limited | 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4- methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitrile as USP30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis |
CN112047933B (zh) * | 2020-10-15 | 2022-06-14 | 郑州大学 | 喹唑啉酮类usp7抑制剂及其制备方法和应用 |
GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
GB202200753D0 (en) | 2022-01-21 | 2022-03-09 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2796417A (en) * | 1952-04-03 | 1957-06-18 | American Cyanamid Co | Quinazolone compounds and methods of making the same |
US3073826A (en) * | 1960-10-20 | 1963-01-15 | Mead Johnson & Co | 3-pyrrolidylmethyl-4-quinazolones |
WO1993012795A1 (en) * | 1985-08-30 | 1993-07-08 | Glazer Edward A | Quinazolin-4(3h)-one derivatives as anticoccidial agents |
FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
US7842522B2 (en) | 2001-10-19 | 2010-11-30 | Applied Nanotech Holdings, Inc. | Well formation |
AR046787A1 (es) * | 2003-12-05 | 2005-12-21 | Bristol Myers Squibb Co | Agentes antimigrana heterociclicos |
SE0303280D0 (sv) | 2003-12-05 | 2003-12-05 | Astrazeneca Ab | Novel compounds |
NZ551004A (en) * | 2004-04-02 | 2010-07-30 | Prana Biotechnology Ltd | Neurologically-active compounds |
SE0401656D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
WO2006012577A2 (en) * | 2004-07-22 | 2006-02-02 | Bayer Pharmaceuticals Corporation | Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake |
KR20070048798A (ko) * | 2004-08-31 | 2007-05-09 | 아스트라제네카 아베 | 퀴나졸리논 유도체 및 이것의 b-raf 억제제로서의 용도 |
WO2006072048A2 (en) | 2004-12-30 | 2006-07-06 | The Trustees Of Princeton University | Compositions and methods for identifying modulators of hausp |
US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
ATE411300T1 (de) | 2005-08-05 | 2008-10-15 | Hybrigenics Sa | Neue cysteine protease hemmers und ihre therapeutische anwendungen |
EA200800549A1 (ru) | 2005-09-06 | 2008-08-29 | Смитклайн Бичем Корпорейшн | Региоселективный способ получения бензимидазолтиофенов |
EP2044026B1 (en) | 2006-06-22 | 2014-03-26 | Prana Biotechnology Limited | Method of treatment of glioma brain tumour |
US20080188498A1 (en) * | 2007-02-05 | 2008-08-07 | Radix Pharmaceuticals, Inc. | Pyridopyrimidinone compounds with antimalarial activity |
CA2737219C (en) * | 2008-08-11 | 2017-02-28 | Tracy Keller | Halofuginone analogs for inhibition of trna synthetases and uses thereof |
EP2358202B1 (en) | 2008-11-03 | 2016-06-15 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
EP2357176A1 (en) | 2010-01-15 | 2011-08-17 | Hybrigenics S.A. | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 |
EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
-
2011
- 2011-09-02 EP EP11306096A patent/EP2565186A1/en not_active Withdrawn
-
2012
- 2012-08-29 PT PT127510808T patent/PT2751092T/pt unknown
- 2012-08-29 JP JP2014527641A patent/JP6059228B2/ja not_active Expired - Fee Related
- 2012-08-29 WO PCT/EP2012/066741 patent/WO2013030218A1/en active Application Filing
- 2012-08-29 SG SG11201400205QA patent/SG11201400205QA/en unknown
- 2012-08-29 US US14/241,923 patent/US9546150B2/en active Active
- 2012-08-29 RU RU2014112692A patent/RU2622640C2/ru not_active IP Right Cessation
- 2012-08-29 SI SI201230714A patent/SI2751092T1/sl unknown
- 2012-08-29 PL PL12751080T patent/PL2751092T3/pl unknown
- 2012-08-29 CA CA2847017A patent/CA2847017A1/en not_active Abandoned
- 2012-08-29 BR BR112014004649A patent/BR112014004649A2/pt not_active Application Discontinuation
- 2012-08-29 MX MX2014002489A patent/MX340500B/es active IP Right Grant
- 2012-08-29 KR KR1020147007456A patent/KR20140085430A/ko not_active Application Discontinuation
- 2012-08-29 DK DK12751080.8T patent/DK2751092T3/en active
- 2012-08-29 CN CN201280054148.2A patent/CN103930415B/zh not_active Expired - Fee Related
- 2012-08-29 LT LTEP12751080.8T patent/LT2751092T/lt unknown
- 2012-08-29 EP EP12751080.8A patent/EP2751092B1/en active Active
- 2012-08-29 HU HUE12751080A patent/HUE029418T2/en unknown
- 2012-08-29 ES ES12751080.8T patent/ES2594603T3/es active Active
- 2012-08-29 AU AU2012300944A patent/AU2012300944B2/en not_active Ceased
- 2012-08-31 AR ARP120103228A patent/AR087757A1/es not_active Application Discontinuation
-
2014
- 2014-02-21 TN TNP2014000079A patent/TN2014000079A1/en unknown
- 2014-02-25 MA MA36781A patent/MA35361B1/fr unknown
- 2014-02-27 IL IL231203A patent/IL231203A/en active IP Right Grant
- 2014-02-28 CL CL2014000511A patent/CL2014000511A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201400205QA (en) | Selective and reversible inhibitors of ubiquitin specific protease 7 | |
EP2678018A4 (en) | COMBINATION OF CHINESE HEMMER AND USES THEREOF | |
GB201103526D0 (en) | Selective glycosidase inhibitors and uses thereof | |
HK1216248A1 (zh) | 纖溶酶原激活物抑制因子- 抑制劑和其使用方法 | |
EP2723753A4 (en) | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | |
SI2523938T1 (sl) | Derivati amidoakrina, ki so uporabni kot selektivni inhibitorji specifične proteaze 7 ubikvitina | |
HK1198827A1 (en) | Dyrk1 inhibitors and uses thereof dyrk1 | |
EP2663312A4 (en) | IRAQ INHIBITORS AND THEIR USE | |
EP2675440A4 (en) | CYSTEINE INHIBITORS PROTEASES, CATHEPSINES | |
EP2619184A4 (en) | DEUBIQUITINASE INHIBITORS AND METHOD FOR THEIR USE | |
ZA201307499B (en) | Compositions and methods comprising serine protease variants | |
EP2569291A4 (en) | GLYCOSIDASE SELECTIVE INHIBITORS AND USES THEREOF | |
EP2638052A4 (en) | SELECTIVE GLYCOSIDASE HEMMER AND ITS USE | |
IL231270A0 (en) | Inhibitors of monooxygenase - 3 - kynurenine, pharmaceutical compositions, and methods of their use | |
EP2726468A4 (en) | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | |
EP2744338A4 (en) | SELECTIVE GLYCOSIDASE HEMMER AND ITS USE | |
EP2726492A4 (en) | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | |
EP2691407A4 (en) | GLYCOSIDASE SELECTIVE INHIBITORS AND USES THEREOF | |
ZA201307956B (en) | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor | |
EP2688899A4 (en) | GLYCOSIDASE SELECTIVE INHIBITORS AND USES THEREOF | |
EP2637503A4 (en) | GLYCOSIDASE SELECTIVE INHIBITORS AND USES THEREOF | |
EP2740734A4 (en) | HCV Protease Inhibitors | |
EP2697246A4 (en) | CYSTEINE PROTEASE SELECTIVE INHIBITORS AND USES THEREOF | |
HK1199252A1 (en) | Inhibitors of nedd8-activating enzyme nedd8- | |
EP2709728A4 (en) | TAU PROTEASE COMPOSITIONS AND METHODS OF USE |